Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A

Zhejiang Tianyu Pharmaceutical Co. Ltd. Class A

SSZSE:300702
20.57
CNY
+0.38
(+1.88%)
0.21EPS
113.73P/E
7.89BMarket Cap
Apr 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.97
3.24
3.48
4.48
4.55
4.53
6.53
7.99
7.34
7.63
7.39
7.53
8.98
10.92
Basic EPS, GAAP
0.14
0.1
0.21
0.51
0.38
0.51
1.81
2.06
0.59
-0.34
0.08
0.16
0.41
0.2
Free Cash Flow per Basic Share
- -
- -
-0.2
0.24
-0.04
-0.31
0.23
0.36
-2.88
-1.65
-1.05
0.5
0.34
- -
Dividend per Share
0.17
0.16
0.1
0.19
0.21
0.11
0.12
0.29
0.32
0.2
0.15
0.2
0.17
0.15
Book Value per Share
1.88
1.89
2.05
2.51
4
4.41
6.21
10.81
10.66
10.04
10.02
10.05
10.46
10.35
Tangible Book Value per Share
1.67
1.69
1.73
2.05
3.52
3.96
5.71
10.08
9.58
8.83
8.74
8.72
9.05
8.81
Basic Weighted Avg Shares
244
240
241
242
261
324
323
324
347
350
342
350
341
347
Sales/Revenue/Turnover
723
777
840
1,082
1,188
1,467
2,111
2,587
2,545
2,667
2,527
2,631
3,061
3,791
Operating Margin (%)
5.97
6.84
8.15
13.99
14.54
15.6
33.51
29.24
9.26
1.52
12.52
6.41
9.94
6.82
Depreciation Expense
- -
42
51
63
76
83
101
136
193
255
305
334
358
- -
Net Income, GAAP
34
24
50
122
100
164
586
667
205
-119
27
56
140
69
Effective Tax Rate (%)
14
9.44
16.07
14.64
15.6
13.55
14.38
13.24
6.29
- -
61.96
28.87
11.91
15.36
Profit Margin (%)
4.64
3.11
5.99
11.3
8.43
11.16
27.75
25.78
8.04
-4.46
1.08
2.13
4.56
1.83
Working Capital
-11
-73
-117
-108
462
464
744
1,671
955
348
388
266
386
411
LT Debt
- -
- -
- -
- -
- -
24
15
57
121
165
216
135
227
482
Total Equity
454
456
496
607
1,288
1,446
2,037
3,547
3,709
3,495
3,488
3,498
3,640
3,647
Return on Invested Capital (%)
- -
3.06
5.54
11.77
7.48
9.46
29.08
22.6
5.49
- -
0.53
1.14
2.85
1.7
Return on Capital (%)
- -
5.54
8.44
14.13
8.79
10.08
29.36
22.62
5.38
- -
0.92
1.78
3.31
1.85
Return on Common Equity (%)
- -
5.31
10.58
22.18
10.57
11.97
33.63
23.89
5.64
-3.3
0.78
1.6
3.91
1.91

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,569
1,531
1,409
LT Borrowings
186
350
455
LT Finance Leases
24
25
27
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
348
348
348
Market Capitalization
8,136
7,015
7,892

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,920
3,135
2,997
Cash, Cash Equivalents & STI
573
635
498
Accounts Receivable, Net
536
728
690
Inventories
1,594
1,542
1,557
Total Current Liabilities
2,456
2,808
2,586
Payables & Accruals
- -
- -
- -
ST Debt
1,569
1,531
1,409
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.48%
0.59%
4.06%
Free Cash Flow
-77.8%
-244.49%
-34.09%
Net Income, GAAP
36.38%
-19.24%
149.78%
Sales/Revenue/Turnover
14.69%
3.67%
16.36%
Total Cash Common Dividend
18.92%
-5.26%
-17.42%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
689
576
667
699
2,631
2025
759
808
- -
774
3,061
2026
812
1,199
1,006
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.04
0.09
-0.08
0.16
2025
0.25
0.18
- -
-0.23
0.41
2026
0.12
0.18
0.13
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.08
0.05
0.03
0.2
2025
0.03
0.08
- -
0.02
0.17
2026
0.03
0.08
0.03
- -
- -

Company Description

CEO
Yong Jun Tu
Full Time Employees
4,686
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Huangyan Jiangkou Chemical Dev Zn Taizhou ZH China 318020
IPO Date
Sep 19, 2017
Business
Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and formulations, primarily targeting chronic disease treatments including cardiovascular, anti-diabetic, anti-atherosclerosis, anticoagulant, anti-asthmatic, and anti-cancer therapies; core products encompass sartan antihypertensives such as azilsartan, azilsartan medoxomil potassium, candesartan cilexetil, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, and valsartan; hypoglycemics including canagliflozin hemihydrate, dapagliflozin, empagliflozin, sitagliptin hydrochloride monohydrate, and vildagliptin; anticoagulants such as apixaban, dabigatran etexilate mesylate, and avatrombopag maleate; antihyperlipidemics like sacubitril valsartan sodium; anti-asthmatics including nebivolol hydrochloride; and oncology APIs such as cabozantinib malate, enzalutamide, ibrutinib, apalutamide, and ribociclib succinate, alongside fine chemicals, CDMO services from clinical phase I to commercial production, and comprehensive process development with CEP/DMF documentation and cGMP/EU GMP compliance. Founded in 1993 with roots in Zhejiang Huangyan Tianyu Chemical Plant and formally registered in 2003, the company is headquartered in Taizhou, Zhejiang Province, China, with additional production bases and R&D centers in Shanghai, Hangzhou, Yancheng, Weifang, and Changzhou; it operates as a national high-tech enterprise and intellectual property demonstration entity, supplying products to leading original and generic pharmaceutical companies in over 70 countries worldwide. Recent developments include approval of a cash dividend for 2024 payable in June 2025, authorization of a share buyback plan in January 2024, participation in private placement financing activities in 2023 involving investors such as Shenzhen Investment Control East China Sea Investment Co., Ltd. and others totaling significant capital infusions, expansion of its API portfolio with new offerings like aprocitentan, brexpiprazole, and elacestrant dihydrochloride, and receipt of an FDA warning letter in February 2025 regarding CGMP compliance for APIs.